UroView: Gallium 68 PSMA–Targeted PET Imaging in Prostate Cancer: Staging and Outcomes
This article features insights from Phillip Kuo, MD, PhD, and Andre Abreu, MD, on gallium 68 PSMA-targeted PET imaging in prostate cancer.
Impact of the Phase III VISION Trial
Andre Abreu, MD, and Phillip Kuo, MD, PhD, on future use of PSMA targeted therapy, including insight on the phase 3 VISION trial, which used 68Ga-PSMA-11 PET/CT to identify patients for targeted treatment with 177Lu-PSMA-617.
Current Availability and Accessibility of Ga-68 PSMA-11
The FDA’s approval of Ga-68 PSMA-11 and its impact on ensuring accessibility of generator versus cyclotron for new radiotracers is discussed from a nuclear medicine perspective.
Evaluating the Sensitivity of PSMA PET Scans
Phillip Kuo, MD, PhD, reviews the sensitivity of PSMA (prostate-specific membrane antigen) PET (positron emission tomography) scans compared to conventional imaging.
PET PSMA for Prostate Cancer: Impact on Patient Journey
Andre Abreu, MD, discusses the rationale behind targeting PSMA (prostate-specific membrane antigen) and its impact on the patient journey from diagnosis to biochemical recurrence.
History and Benefits of Targeting PET PSMA
The history and resultant benefits of PET (positron emission tomography) along with the utilization of PSMA (prostate-specific membrane antigen) PET imaging in treating prostate cancer is discussed.
Prostate Cancer Imaging: Standard of Care and Limitations
Andre Abreu, MD, and Phillip Kuo, MD, PhD, define the standard of care and the limitations in prostate cancer imaging.
Transperineal prostate biopsy: Freehand technique using Trinity system
Abreu’s group at USC provides an overview of the transperineal MRI/TRUS fusion prostate biopsy also utilizing the freehand technique.
2 Clarke Drive Cranbury, NJ 08512